News

Eli Lilly’s early-stage obesity drug causes up to 11% of weight loss in three months
Eli Lilly's (LLY) experimental obesity drug, eloralintide, shows up to 11% weight loss in 12 weeks with minimal side effects in early-stage trial. Read more here.
Novo Nordisk to launch late-stage program to test novel obesity candidate
Novo Nordisk (NVO) plans to start a late-stage clinical program next year to test oral and injectable forms of its new ...
Science Daily3d
Beyond Ozempic: New weight loss drug rivals surgery
Tufts University scientists are aiming to revolutionize the future of weight loss drugs by engineering a new compound that ...
Novo Nordisk, Deep Apple Launch Drug Discovery Alliance For Weight Loss Oral Therapies
Novo Nordisk and Deep Apple ink a deal to develop oral therapies targeting a novel GPCR for cardiometabolic diseases, ...
Acquisitions, Licensing Deals Take Centerstage in Pharma/Biotech Space
SNY, BMY, REGN and others ramp up 2025 dealmaking as pharma/biotech giants chase innovation across key growth areas.